361 studies found for:    "Multiple Sclerosis, Relapsing-Remitting"
Show Display Options
RSS Create an RSS feed from your search for:
"Multiple Sclerosis, Relapsing-Remitting"
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Terminated
Has Results
Minocycline as add-on to Interferon Beta-1a [IFN Beta-1a] (Rebif®) in Relapsing-Remitting Multiple Sclerosis [RRMS]
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: Minocycline;   Drug: Placebo
2 Completed An Observational Study for the Assessment of Compliance and Persistence to Rebif® Therapy of Patients With Relapsing-remitting Multiple Sclerosis (MS) and Evaluation of Potential Factors Influencing These Parameters
Condition: Multiple Sclerosis, Relapsing-Remitting
Intervention:
3 Completed Study to Assess Whether GSK239512 Can Remyelinate Lesions in Subjects With Relapsing Remitting Multiple Sclerosis
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: GSK239512;   Drug: Placebo
4 Completed A Study of Rebif® Compared With Avonex® in the Treatment of Relapsing-remitting Multiple Sclerosis (MS)
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: Rebif®;   Drug: Avonex®
5 Completed
Has Results
A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Biological: Interferon beta-1a;   Biological: Alemtuzumab 12 mg;   Biological: Alemtuzumab 24 mg
6 Completed
Has Results
A Study to Evaluate Rebif® New Formulation (Interferon-beta-1a) in Relapsing Remitting Multiple Sclerosis
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: Rebif® New Formulation (IFN-beta-1a, RNF);   Drug: Placebo
7 Completed Melatonin in Relapsing-Remitting Multiple Sclerosis Patients
Condition: Multiple Sclerosis, Relapsing-Remitting
Intervention: Drug: Melatonin
8 Enrolling by invitation Pilot Trial of Domperidone in Relapsing-Remitting Multiple Sclerosis (RRMS)
Condition: Multiple Sclerosis, Relapsing-Remitting
Intervention: Drug: Domperidone
9 Withdrawn QOLBET Quality Of Life in Patients With Early Relapsing-remitting Multiple Sclerosis Treated With BETaferon® in Korea
Condition: Multiple Sclerosis, Relapsing-Remitting
Intervention: Drug: Interferon beta 1-b (Betaferon/Betaseron, BAY86-5046)
10 Recruiting Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS).
Conditions: Multiple Sclerosis, Relapsing-Remitting;   Multiple Sclerosis
Intervention: Drug: dimethyl fumarate
11 Completed
Has Results
A Safety and Efficacy Study of Oral Cladribine in Subjects With Relapsing-remitting Multiple Sclerosis (RRMS)
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: Cladribine 5.25 mg/kg;   Drug: Cladribine 3.5 mg/kg;   Other: Placebo
12 Not yet recruiting Investigation of the Effect of Dimethyl Fumarate on T Cells in Patients With Relapsing Remitting Multiple Sclerosis
Condition: Multiple Sclerosis, Relapsing-Remitting
Intervention: Drug: Dimethyl fumarate
13 Terminated A First Time in Human Study Exploring Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK2618960 in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: Part A: 100 mg/mL GSK2618960;   Drug: Part A: matching placebo;   Drug: Part B: Dose of GSK2618960 decided from Part A;   Drug: Part B: matching placebo;   Drug: Part C: Dose of GSK2618960 decided from Part A and B
14 Completed
Has Results
Extension of Prior Study Evaluating Safety and Tolerability of Two Doses of Betaseron® to Treat Relapsing-remitting Multiple Sclerosis
Condition: Multiple Sclerosis, Relapsing-Remitting
Intervention: Drug: Interferon beta 1b (Betaseron, BAY86-5046)
15 Recruiting A Trial for Evaluating Both Safety and Preliminary Efficacy of a Single Infusion of Stimulated Autologous CD4+T Cells in Patients With Relapsing- Remitting Multiple Sclerosis
Condition: Multiple Sclerosis, Relapsing-Remitting
Intervention: Biological: Autologous CD4+T cells stimulated and expanded ex vivo by a MOG peptide modified by the introduction of a thioreductase motif into the flanking residues of the T cell epitope
16 Completed Post-Authorization Observational Study to Evaluate Cognition and Fatigue in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Treated With Rebif®
Condition: Multiple Sclerosis, Relapsing-Remitting
Intervention: Drug: Rebif (Interferon beta-1a)
17 Recruiting Effectiveness of DMF (Dimethyl Fumarate) and Its Impact on PROs (Patient Reported Outcomes) in Treatment-Naive or Suboptimal IFN (Interferon) or GA (Glatiramer Acetate) Responders With RRMS (ImPROve)
Conditions: Multiple Sclerosis, Relapsing-Remitting;   Relapsing-Remitting Multiple Sclerosis
Intervention: Drug: dimethyl fumarate
18 Recruiting Observational Study of Rebismart®2.0 + MSdialog™ in Subjects With Remitting Multiple Sclerosis (ADHERQOL)
Condition: Multiple Sclerosis, Relapsing-remitting
Interventions: Device: RebiSmart®2.0;   Device: MSdialog™
19 Recruiting Rebif® Rebidose® Versus Rebiject II® Ease-of-Use
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Device: Rebif® Rebidose®;   Device: Rebiject II®
20 Not yet recruiting Biological Activity and Safety of Low Dose IL2 in Relapsing Remitting Multiple Sclerosis
Condition: Relapsing Remitting Multiple Sclerosis
Intervention: Drug: IL2

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years